Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Commercial plasma alpha1-antitrypsin (Prolastin) contains a conformationally inactive, latent component.

The European respiratory journal - 1 Mar 1997

Lomas D A, Elliott P R, Carrell R W

Abstract excerpt

Fractionated plasma alpha1-antitrypsin is widely-used as replacement therapy in patients with Z alpha1-antitrypsin deficiency-related emphysema. We have recently shown that purified antitrypsin may be induced to adopt an inactive latent conformation by heating at high temperatures in stabilizing concentrations of sodium citrate. Such a conformation was predicted to be present in commercial preparations of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to alpha 1-Antitrypsin
Share to alpha 1-Antitrypsin Deficiency
Share to Blotting, Western

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cattle

Share to Electrophoresis, Polyacrylamide Gel

Share to Phenotype

Share to Protein Conformation

Share to Pulmonary Emphysema

Source

Identifiers

PMID: 9073003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Commercial plasma alpha1-antitrypsin (Prolastin) contains a conformationally inactive, latent component.PMID 9073003Read ↗

The Z type variation of human alpha 1-antitrypsin causes a protein folding defect.Semantic proximity Read ↗

Why has it been so difficult to prove the efficacy of alpha-1-antitrypsin replacement therapy? Insights from the study of disease pathogenesis.Semantic proximity Read ↗

A Review of α1-Antitrypsin DeficiencySemantic proximity Read ↗

Alpha 1-antitrypsin deficiency.Semantic proximity Read ↗

Current status of alpha-1-antitrypsin replacement therapy: recommendations for the management of patients with severe hereditary deficiency. Ad Hoc Committee on Alpha-1-Antitrypsin Replacement Therapy of the Standards Committee, Canadian Thoracic Society.Semantic proximity Read ↗

Mysteries of α1-antitrypsin deficiency: emerging therapeutic strategies for a challenging diseaseSemantic proximity Read ↗

Development of a chemically modified recombinant α1-antitrypsin mutant expressed in E. coli for therapeutic applications.Semantic proximity Read ↗

Historical role of alpha-1-antitrypsin deficiency in respiratory and hepatic complications.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.